An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016).
Shin Wha LeeYong-Man KimYoung-Tae KimSoon Beom KangPublished in: Journal of gynecologic oncology (2016)
Genexol-PM combined with carboplatin was well tolerated as a first-line treatment, and good responses were observed in patients with advanced ovarian cancer. Based on these results, we recommended a dose of 300 mg/m² or less for a phase II study.
Keyphrases
- phase ii study
- open label
- locally advanced
- phase iii
- drug delivery
- phase ii
- placebo controlled
- study protocol
- clinical trial
- air pollution
- particulate matter
- palliative care
- double blind
- squamous cell carcinoma
- heavy metals
- rectal cancer
- cross sectional
- cancer therapy
- randomized controlled trial
- drug release
- water soluble